NeuroVive receives Vinnova funding to support development of NV354, a novel treatment for genetic mitochondrial disorders
Lund, 15 November, 2018- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in ...